At a glance

Roche continues driving one of this industry’s best product pipelines. In 2019, we invested about one fifth of the company’s sales to develop new tests and medicines for patients in need of new options. A leader in oncology, we are now also entering new disease areas with very low incidence rates. These include multiple sclerosis, haemophilia and neuroscience disesases.

Trang cá độ bóng đá uy tín* CER = Constant Exchange Rates (average full year 2018)

patient story Patient Story

Ike began working with the breast cancer brand team at Roche to highlight what matters to the patient.

youtube play Ike tells us about her work as a patient consultant